相关实验视频
Updated: Jun 19, 2025

05:17
Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
Published on: April 18, 2025
124
阿尔茨海默病诊断中的身体:一篇综述
Daniil Abramchuk1, Alevtina Voskresenskaya2, Ilia Kuzmichev3
1Chemistry Department, Lomonosov Moscow State University, Leninskie gory 1,3, 119991, Moscow, Russia; Department of Materials Science of Semiconductors and Dielectrics, National University of Science and Technology (MISIS), Leninskiy prospect 4, 101000, Moscow, Russia.
European journal of medicinal chemistry
|July 25, 2024
概括
开发新的光探针是早期发现阿尔茨海默病 (AD) 的关键. 基于BODIPY的传感器提供了一种低成本,安全和有效的方法来可视化AD的特征,帮助诊断和治疗.
科学领域:
- 药用化学 医学化学
- 神经退行性疾病 神经退行性疾病
- 生物医学传感传感器
背景情况:
- 阿尔茨海默病 (AD) 的诊断和治疗是神经退行性疾病研究中的关键挑战.
- 目前用于AD相关蛋白质检测的低成本,可靠的传感器的局限性推动了对新型分子工具的需求.
- 光学光探头,特别是BODIPY衍生品,由于其安全性,成本效益和实时可视化能力而具有吸引力.
研究的目的:
- 审查BODIPY衍生品的开发和应用,作为阿尔茨海默病特征的光传感器.
- 总结这些探测器从2009年到2023年的设计策略,光学特性和生物活动.
- 突出基于BODIPY的探针的潜力,以改善AD诊断.
主要方法:
- 基于BODIPY的光探针用于AD检测的综合文献综述 (2009-2023年).
- 对探设计策略的分析,以粉样β斑块,可溶性寡合体和神经纤维状结为目标.
- 对审查的探针的光学特性,光稳定性,毒性和细胞透性的评估.
主要成果:
- 许多BODIPY衍生品已被设计为各种AD病理特征的光传感器.
- 这些探针显示出高光稳定性,低毒性和细胞透性,适合体内应用.
- 研究表明,这些传感器对于检测Aβ斑块,可溶性寡合物,NFT和监测铜离子度和粘度变化的有用性.
结论:
- 基于BODIPY的光探针代表了检测阿尔茨海默病生物标志物的有前途的传感器类.
- 它们的多功能设计和有利的光学特性促进了先进的诊断工具的开发.
- 这一领域的持续研究为推进早期阿尔茨海默病检测和治疗策略提供了巨大的潜力.
相关概念视频
Alzheimer's Disease: Overview
456
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
456
Alzheimer's Disease: Treatment
172
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
172

